<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">nid-492</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома. Разработчик: Научное общество нефрологов России. Утверждены Президиумом правления Научного общества нефрологов России 18 декабря 2014 г.</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Статья</surname><given-names>Редакционная</given-names></name><name name-style="western" xml:lang="en"><surname>Article</surname><given-names>Editorial</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>29</day><month>08</month><year>2024</year></pub-date><volume>17</volume><issue>3</issue><fpage>242</fpage><lpage>264</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Статья Р., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Статья Р.</copyright-holder><copyright-holder xml:lang="en">Article E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/492">https://journal.nephro.ru/jour/article/view/492</self-uri><abstract><p>Разработчик: Научное общество нефрологов России Рабочая группа: Профессор Козловская Н.Л. Профессор Прокопенко Е.И. Доцент Эмирова Х.М. К.м.н. Серикова С.Ю. Утверждены Президиумом правления Научного общества нефрологов России 18 декабря 2014 г. г. Москва 2014 г.</p></abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ariceta G., Besbas N., Johnson S. et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.</mixed-citation><mixed-citation xml:lang="en">Ariceta G., Besbas N., Johnson S. et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Barbour T., Johnson S., Cohney S. et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 2012; 27: 2673-2685.</mixed-citation><mixed-citation xml:lang="en">Barbour T., Johnson S., Cohney S. et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 2012; 27: 2673-2685.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Campistol J.M., Arias M., Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013; 33(1): 27-45.</mixed-citation><mixed-citation xml:lang="en">Campistol J.M., Arias M., Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013; 33(1): 27-45.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cataland SR, Haifeng M.Wu. Atypical haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopatheis. Eur J Intern Med. 2013;24:486-491.</mixed-citation><mixed-citation xml:lang="en">Cataland SR, Haifeng M.Wu. Atypical haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopatheis. Eur J Intern Med. 2013;24:486-491.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fakhouri F, Delmas Y, Provot F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. AJKD 2013; http://dx.doi.org/10.1053/ j.ajkd.2013.07.011</mixed-citation><mixed-citation xml:lang="en">Fakhouri F, Delmas Y, Provot F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. AJKD 2013; http://dx.doi.org/10.1053/ j.ajkd.2013.07.011</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kavanagh D., Goodship T.H.J. Atypical hemolytic uremic syndrome. Curr Opin Hematol 2010; 17(5):432-438.</mixed-citation><mixed-citation xml:lang="en">Kavanagh D., Goodship T.H.J. Atypical hemolytic uremic syndrome. Curr Opin Hematol 2010; 17(5):432-438.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Laurence J. Atypical haemolytic uraemic syndrome (aHUS): treating the patient. Clin Adv Hematol Oncol 2013; 11(10), Suppl.15:3-15</mixed-citation><mixed-citation xml:lang="en">Laurence J. Atypical haemolytic uraemic syndrome (aHUS): treating the patient. Clin Adv Hematol Oncol 2013; 11(10), Suppl.15:3-15</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Legendre CM, Licht C, Greenbaum LA et al. Terminal complement inhibitor eculizumab in atypical haemolytic uraemic syndrome. N Engl J Med. 2013; 368(23):2169-2181.</mixed-citation><mixed-citation xml:lang="en">Legendre CM, Licht C, Greenbaum LA et al. Terminal complement inhibitor eculizumab in atypical haemolytic uraemic syndrome. N Engl J Med. 2013; 368(23):2169-2181.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical haemolytic uraemic syndrome. Semin Thromb Hemost 2010:36:673-681</mixed-citation><mixed-citation xml:lang="en">Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical haemolytic uraemic syndrome. Semin Thromb Hemost 2010:36:673-681</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Лора Ш., Фремю-Бачи В. Атипичный гемолитико- уремический синдром// Нефрология.- 2012; т. 16, №2, с.16-48.</mixed-citation><mixed-citation xml:lang="en">Лора Ш., Фремю-Бачи В. Атипичный гемолитико- уремический синдром// Нефрология.- 2012; т. 16, №2, с.16-48.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Meri S. Complement activation in deseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013; http://dx.doi.org/10.1016/ j.ejim.2013.05.009</mixed-citation><mixed-citation xml:lang="en">Meri S. Complement activation in deseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013; http://dx.doi.org/10.1016/ j.ejim.2013.05.009</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is this, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012:617-25.</mixed-citation><mixed-citation xml:lang="en">Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is this, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012:617-25.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.</mixed-citation><mixed-citation xml:lang="en">Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Noris M., Caprioli J, Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844-1859</mixed-citation><mixed-citation xml:lang="en">Noris M., Caprioli J, Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844-1859</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Scully M., Hunt B.J., Bemjamin S. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopatheis. BJH 2012; 158 (3): 323-335.</mixed-citation><mixed-citation xml:lang="en">Scully M., Hunt B.J., Bemjamin S. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopatheis. BJH 2012; 158 (3): 323-335.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Scully M., Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. BJH 2014; doi:10.1111/bjh.12718</mixed-citation><mixed-citation xml:lang="en">Scully M., Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. BJH 2014; doi:10.1111/bjh.12718</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH.2009;148:37-47</mixed-citation><mixed-citation xml:lang="en">Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH.2009;148:37-47</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai HM. Thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. An Update. Hematol Oncol Clin N Am 2013;27:565-584</mixed-citation><mixed-citation xml:lang="en">Tsai HM. Thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. An Update. Hematol Oncol Clin N Am 2013;27:565-584</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zuber J., Fakhouri F., Roumenina L.T. et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopahties. Nat. Rev. Nephrol. 2012; 8, 643-657.</mixed-citation><mixed-citation xml:lang="en">Zuber J., Fakhouri F., Roumenina L.T. et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopahties. Nat. Rev. Nephrol. 2012; 8, 643-657.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zuber J., Le Quintrec M, Sberro-Soussan R. Et al. New Insight into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23-35</mixed-citation><mixed-citation xml:lang="en">Zuber J., Le Quintrec M, Sberro-Soussan R. Et al. New Insight into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23-35</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
